Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Rhea-AI Summary
Creative Medical Technology Holdings (NASDAQ: CELZ) received a USPTO Notice of Allowance for U.S. patent application 17/931,868 titled “Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells.” The patent covers cell-free MyeloCelz™ exosome technology designed to induce antigen-specific immune tolerance and suppress autoimmune destruction of insulin-producing pancreatic beta cells in Type 1 diabetes.
The allowed claims include use of these exosomes alone or with tolerance-promoting agents such as antibodies, cellular therapies and small molecules. According to Creative Medical, this patent strengthens a multi-layered IP estate supporting its diabetes portfolio, including CELZ-201 for newly diagnosed T1D, CELZ-101 with FDA Orphan Drug Designation for brittle T1D, and CELZ-001 for late-stage Type 2 diabetes. The company reports approximately 60 issued and pending patents overall, including seven issued U.S. patents and 39 pending U.S. applications, and plans to advance clinical programs and explore licensing and partnership opportunities.
Positive
- USPTO Notice of Allowance for exosome-based Type 1 diabetes patent (Application 17/931,868)
- IP estate scale: about 60 issued patents and pending applications across platforms
- U.S. portfolio: seven issued patents plus 39 pending U.S. applications
- Patent terms: prior diabetes- and immunology-related patents with protection into 2042–2043
- Pipeline breadth: diabetes programs CELZ-201, CELZ-101 (Orphan Drug) and CELZ-001 supported by overlapping IP
Negative
- MyeloCelz™ remains investigational with no approved products
- This announcement includes no new clinical data for MyeloCelz™ or diabetes programs
- The release reports no new FDA authorizations related to the MyeloCelz™ platform
News Explained
The USPTO notice covers an allowed application rather than an issued patent: Creative Medical says formal issuance remains ahead, and the release adds no new clinical data or FDA authorization; MyeloCelz™ therefore remains investigational while the stated IP position advances.
Market reaction after exosome patent allowance: CELZ +117.10%
Following this news, CELZ has gained 117.10%, reflecting a significant positive market reaction. Argus tracked a peak move of +53.6% during the session. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner has triggered 188 alerts so far, indicating very high trading interest and price volatility. The stock is currently trading at $1.45. Trading volume is exceptionally heavy at 99.9x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 01 | Mid-year update | Positive | -12.4% | Program progress and positive clinical updates across regenerative medicine and biodefense initiatives |
| Jun 30 | Warrant exercise | Negative | +79.0% | Discounted warrant exercises generated proceeds alongside issuance of additional warrants |
| Jun 22 | FDA trial clearance | Positive | -13.4% | FDA cleared an ADAPT trial expansion with a 15-patient cohort |
| Jun 16 | AI program update | Positive | -6.3% | Project PHOENIX entered nationwide virtual data collection targeting at least 1,000 veterans |
| Apr 28 | Clinical pilot results | Positive | -2.2% | Ultrasome pilot reported a 93% response rate without serious adverse events |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CELZ historically diverged from the initial direction suggested by recent company announcements, with negative 24-hour reactions following all five selected events.
Key Terms
notice of allowance regulatory
exosomes medical
antigen-specific immune tolerance medical
myeloid suppressor cell activity medical
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy
PHOENIX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled “Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells” (U.S. Application No. 17/931,868).
Once formally issued, the patent will extend Creative Medical’s intellectual property protection around its proprietary MyeloCelz™ platform, a cell-free exosome technology derived from stem-cell-programmed myeloid cells that is designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells that underlies Type 1 diabetes (T1D). The allowed claims cover the use of these exosomes alone, or in combination with other tolerance-promoting agents such as antibodies, cellular therapies and small molecules, to selectively shut down the immune cells responsible for attacking the pancreas while preserving the immune system’s ability to fight infection and disease.
Strengthening a Multi-Layered Patent Estate Around Creative Medical's Diabetes Franchise
This Notice of Allowance is the latest in a series of USPTO actions strengthening Creative Medical’s intellectual property position across its immunology and endocrinology pipeline. It follows the Company’s prior Notices of Allowance covering “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity” and “Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells,” both of which were subsequently issued as U.S. Patent Nos. 12,931,925 and 12,385,011, respectively, providing protection into 2042 and 2043.
The newly allowed exosome patent directly complements the Company’s broader diabetes portfolio, which spans multiple stages of disease and mechanisms of action: CELZ-201 (olastrocel/AlloStem®), currently being evaluated in the FDA-cleared CREATE-1 trial for newly diagnosed T1D; CELZ-101 (etaroleucel/ImmCelz®), which holds FDA Orphan Drug Designation for use alongside pancreatic islet transplantation in brittle T1D; and CELZ-001, the Company’s program for late-stage Type 2 diabetes. Creative Medical’s overall intellectual property estate now comprises approximately 60 issued patents and pending applications, with seven issued U.S. patents and 39 pending U.S. applications on file with the USPTO.
“Each new Notice of Allowance adds another layer of protection around the core biology that differentiates our platform,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “This exosome-based approach gives us a cell-free way to pursue the same antigen-specific tolerance mechanism we are already advancing clinically with CELZ-101 and CELZ-201. Building overlapping IP protection across both our cellular and cell-free diabetes programs is a deliberate strategy to maximize the long-term value of our platform for patients and shareholders alike.”
A Large and Growing Market Opportunity in Type 1 Diabetes
Type 1 diabetes remains a lifelong autoimmune condition with no approved cure. According to the U.S. Centers for Disease Control and Prevention, approximately 2.1 million Americans, including 1.8 million adults and 314,000 children and adolescents, are living with diagnosed T1D. Independent market research estimates the global Type 1 diabetes market at roughly
What Comes Next
Following receipt of this Notice of Allowance, Creative Medical plans to:
- Complete formal issuance of the patent and continue building out its exosome-related intellectual property estate.
- Advance its clinical-stage CELZ-101 and CELZ-201 diabetes programs, including continued enrollment and data generation.
- Evaluate strategic pathways, including potential licensing and partnership discussions, that leverage its expanded patent protection across the MyeloCelz™, ImmCelz® and AlloStem® platforms.
About MyeloCelz™
MyeloCelz™ is Creative Medical’s cell-free platform focused on harnessing the innate immune system, complementing the Company’s ImmCelz® platform, which primarily engages T and B cells, and its Ultrasome™ platform, the Company’s cell-free regenerative technology for orthopedic applications. MyeloCelz™-derived exosomes are designed to promote antigen-specific immunological tolerance by modulating myeloid suppressor cell activity, with lead application in the prevention and treatment of Type 1 diabetes. MyeloCelz™ remains investigational; no product has been approved, and this release announces no new clinical data or FDA authorization for the program.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine therapies derived from adult and perinatal stem cell technologies. With a diversified pipeline spanning orthopedics, immunotherapy, endocrinology, urology, and gynecology, the Company is committed to translating cutting-edge science into transformative, accessible therapies for patients with high unmet medical needs. For more information, please visit www.creativemedicaltechnology.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding patent prosecution and issuance, regulatory pathways, clinical development milestones, potential therapeutic applications, and the Company’s strategic outlook. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These risks include, but are not limited to, the risk that a Notice of Allowance does not guarantee that a patent will ultimately issue or that issued claims will provide meaningful commercial protection, as well as clinical trial results, regulatory decisions, manufacturing challenges, market conditions, and other factors described in the Company’s filings with the Securities and Exchange Commission. Creative Medical Technology Holdings assumes no obligation to update such statements except as required by law.
Investor & Media Contacts
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com
Investor Relations
Devin Sullivan — The Equity Group Inc.
dsullivan@theequitygroup.com
Conor Rodriguez — The Equity Group Inc.
crodriguez@theequitygroup.com
